The Value Add of Digital Health in Pharma

The digitization across healthcare has opened up a sleuth of opportunities. In particular, digital diagnostics (DDx), digital therapeutics (DTx), and digital biomarkers, have been enhancing the ability to capture and analyze large quantities of real world data (RWD) from more diverse populations.  

Pharma companies are taking a growing interest in these technologies with potential benefits across drug discovery, clinical trials and beyond. Pharmaceutical companies are selectively exploring technologies and use cases but very few disseminate information about initiatives in progress. With any nascent technology, it takes time to evaluate whether the economics are favorable and how the benefits are distributed. Pharmaceutical companies are still working out how to measure the returns of their digital initiatives specifically, defining  ROI or value on their investments. 

Join senior pharma leaders to discuss how companies are investing in digital health initiatives such as DDx, DTx, and digital biomarkers, and what ROI or value has been achieved to date: 

• How is pharma investing in DDx, DTx, and/or digital biomarkers?
• How can we measure KPIs for and value from digital health initiatives? 
• How is ROI defined? How is pharma thinking about the different ways in which digital health adds value to end-customers and the core business?